Senti Bio Doses First Patient In Phase 1 Trial Of SENTI-202 In Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Senti Bio Doses First Patient In Phase 1 Trial Of SENTI-202 In Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Senti Bio 爲復發或難治性血液系統惡性腫瘤（包括急性髓系白血病）的 SENTI-202 第 1 期試驗中的第一位患者服藥
Senti Bio Doses First Patient In Phase 1 Trial Of SENTI-202 In Relapsed Or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia
Senti Bio 爲復發或難治性血液系統惡性腫瘤（包括急性髓系白血病）的 SENTI-202 第 1 期試驗中的第一位患者服藥
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。